# A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors

> **NCT07131202** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Forlong Biotechnology Co., Ltd** · enrollment: 130 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** FL115+PD-1

## Key facts

- **NCT ID:** NCT07131202
- **Lead sponsor:** Suzhou Forlong Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2026-12-05
- **Final completion:** 2028-12-05
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131202, "A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07131202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*